<DOC>
	<DOC>NCT00332657</DOC>
	<brief_summary>The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.</brief_summary>
	<brief_title>Anecortave Acetate Risk Reduction Trial (AART)</brief_title>
	<detailed_description />
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Dry AMD in study eye, Wet AMD nonstudy eye. Other protocoldefined inclusion criteria may apply. Under 50. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>